Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia
暂无分享,去创建一个
H. Dombret | J. Bibault | C. Preudhomme | P. Rousselot | Aline Renneville | O. Nibourel | S. Quief | M. Figeac | S. Castaigne | B. Gruson | C. Rodriguez | Shéhérazade Sebda | N. Hélevaut
[1] Jiajie Zhang,et al. PEAR: a fast and accurate Illumina Paired-End reAd mergeR , 2013, Bioinform..
[2] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[3] M. Grunwald,et al. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance , 2013, International Journal of Hematology.
[4] John D Pfeifer,et al. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data. , 2013, The Journal of molecular diagnostics : JMD.
[5] E. Paietta,et al. Minimal residual disease in acute myeloid leukemia: coming of age. , 2012, Hematology. American Society of Hematology. Education Program.
[6] C. Schiffer,et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia , 2012, Leukemia.
[7] M. Heuser,et al. Next‐generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3‐ITD or NPM1 mutations , 2012, Genes, chromosomes & cancer.
[8] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[9] C. Preudhomme,et al. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. , 2012, Leukemia research.
[10] Joshua F. McMichael,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.
[11] T. Haferlach,et al. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia , 2011, Leukemia.
[12] N. Caruccio. Preparation of next-generation sequencing libraries using Nextera™ technology: simultaneous DNA fragmentation and adaptor tagging by in vitro transposition. , 2011, Methods in molecular biology.
[13] K. Döhner,et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. , 2009, Blood.
[14] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[15] W. Tse,et al. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics , 2009, Journal of hematology & oncology.
[16] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[17] A. Mead,et al. Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication , 2008, British journal of haematology.
[18] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[19] D. Steinbach,et al. What do we mean by sensitivity when we talk about detecting minimal residual disease? , 2008, Leukemia.
[20] M. Caligiuri,et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. , 2008, Blood.
[21] A. Mead,et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. , 2007, Blood.
[22] Gregory Kucherov,et al. mreps: efficient and flexible detection of tandem repeats in DNA , 2003, Nucleic Acids Res..
[23] W. Hiddemann,et al. Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy , 2002, Leukemia.